Next Article in Journal
Triterpene Derivatives as Relevant Scaffold for New Antibiofilm Drugs
Previous Article in Journal
Formulations of Curcumin Nanoparticles for Brain Diseases
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Biomolecules 2019, 9(2), 57;

Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing

Rheumatology Department, Moscow Regional Research and Clinical Institute, Shchepkina, 61/2, Moscow 129110, Russia
Pfizer Ltd., Maidenhead, Berkshire SL6 6RJ, UK
Author to whom correspondence should be addressed.
Received: 15 October 2018 / Revised: 4 February 2019 / Accepted: 5 February 2019 / Published: 11 February 2019
Full-Text   |   PDF [839 KB, uploaded 19 February 2019]   |  


Physician awareness and perceptions towards biosimilars are important factors in their adoption to clinical practice. Our objectives were to assess levels of knowledge and attitudes towards biosimilars and key policies on their use among Russian physicians, define the level of interest in new information on biosimilars, and determine what evidence drives treatment decisions in Russia. Physicians with awareness of biologics across different specialties and regions of Russia completed an online survey. A Likert and other rating scales were used to collect opinions, which were summarized descriptively. Responses of subgroups of respondents were compared using t-tests. Among 206 respondents (n = 51 rheumatologists; n = 53 gastroenterologists; n = 50 hematologists; n = 52 oncologists), 66% had positive impressions regarding the introduction of biosimilars in Russia. Overall, 80% lacked understanding of the differences between biosimilars and generics. In all, 67% supported prescribing biologics by distinguishable names and were negative about tender policies limiting choice of therapies for patients. The majority believed in mandatory publication of clinical trial results on biosimilars (94%), agreed biosimilars should be subject to rigorous post-marketing surveillance (98%), and expressed willingness to learn more about biosimilars (94%). Biosimilar education among Russian physicians is required, which may help shape balanced and evidence-based policies for biosimilars in Russia. View Full-Text
Keywords: awareness; biosimilars; education; physicians; perceptions; Russia awareness; biosimilars; education; physicians; perceptions; Russia

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Karateev, D.; Belokoneva, N. Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing. Biomolecules 2019, 9, 57.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top